Moderna is paring back gains, but Merck stock remains a buy

Moderna (MRNA) shares are paring back some of their recent gains on Thursday morning – but a Morgan Stanley analyst believes Merck (MRK) stock remains a buy following blockbuster cancer drug trial res...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。